Skip to main content
Equibles
ONC logo

ONC · BeOne Medicines Ltd. · Metrics

Track ONC — free

Use ONC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ONC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$365.94 +0.67 (+0.18%) At close · Sep 30
Rebalance outlook locked
Market Cap
$40.82B
Shares
113.12M
Volume · Sep 30 328.88K Avg daily vol (3M) 388.06K

ONC metrics

34 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$365.94
Market cap
$40.82B

Price action

20 metrics
Price change (1W)
-0.8%
Price change (30D)
+1.6%
Price change (3M)
+28.2%
Price change (6M)
+23.0%
Price change (YTD)
+20.2%
Price change (1Y)
+9.7%
Trailing year
Price change (5Y)
+1.0%
52-week high
$377.47
52-week low
$260.27
Change from 52-week high
-3.2%
Change from 52-week low
+40.3%
Annualized volatility
35.2%
Annualized volatility (3M)
29.1%
Beta
0.9
RSI (14D)
56.9
Price vs SMA 50
+4.1%
Price vs SMA 200
+14.3%
Avg volume (3M)
388,004
Relative volume
1.0
Average dollar volume
$132.32M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
113.12M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
—
Total assets
—
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
283
13F filer change QoQ
0
Institutional ownership
31.1%

Short interest

3 metrics
Short interest
1.5%
Latest settlement · 4.5 days to cover
Days to cover
4.5d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$320.71M
Insider-sentiment score
36 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1651308 CUSIP 07725L102 13F (30d) 10 filings 8 filers Visit website Investor relations